Evotec AG has made a €15m investment in artificial intelligence-driven drug discovery company, Exscientia Ltd. – becoming its first strategic shareholder.
The two companies are not strangers and this buy in builds upon their existing drug discovery partnership in immuno-oncology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?